gtag('config', 'UA-131743784-1');

Developed API’s

NSAIDAnti - TussiveAnti-DepressantAnti-OsteoporoticMuscle RelaxantInsomniaAntigoutNeutraceuticalAnti- AlcoholismAntiosteoporotic

Celecoxib

CAS NO. 169590-42-5
Therapeutic Class: Selective Non-steroidal Anti inflammatory drug (NSAID)
Pharmacopoeia compliance: USP/Ph.Eur
Certifications: Written Confirmation

Celecoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain in adults, painful menstruation and juvenile rheumatoid arthritis in people two years or older.

A highly selective reversible inhibitor of the COX-2 isoform of cyclooxygenase, celecoxib inhibits the transformation of arachidonic acid to prostaglandin precursors. Therefore it has antipyretic, analgesic, anti-inflammatory properties.

 



Etoricoxib

CAS NO. 202409-33-4
Therapeutic Class: Anti-inflammatory, analgesic
Pharmacopoeia compliance: USP/Ph.Eur
Certifications:

Etoricoxib is indicated for the treatment of rheumatoid arthritis, psoriatic, arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Approved indications differ by country.

 

Selective COX-2 inhibitors show less activity on COX-1 compared to traditional non-steroidal anti-inflammatory drugs (NSAID). This reduced activity is the cause of reduced gastrointestinal side effects, as demonstrated in several large clinical trials performed with different coxibs.

Butamirate Citrate

CAS NO. 18109-81-4
Therapeutic Class: Anti-tussive
Pharmacopoeia compliance: In house
Certifications:

Butamirate Citrate is a cough suppressant. A study found it to bind to the cough center in the medulla oblongata.



Butethamate Citrate

CAS NO. 3639-12-1
Therapeutic Class: Anti-tussive
Pharmacopoeia compliance: In house
Certifications:

ButethamateCitrate is a cough suppressant. A study found it to bind to the cough center in the medulla oblongata.

Bupropion Hydrochloride

CAS NO. 31677-93-7
Therapeutic Class: Antidepressant
Pharmacopoeia compliance: USP
Certifications:

Bupropion Hydrochloride is sold under the brand names Wellbutrin and Zyban among others. It is a medication primarily used as Anti-depressant and smoking cessation aid. It is an effective antidepressant on its own, but is also used as an add-on medication in cases of incomplete response to first-line SSRI antidepressants.

Raloxifene Hydrochloride

CAS NO. 82640-04-8
Therapeutic Class: Antiosteoporotic
Pharmacopoeia compliance: USP/Ph.Eur
Certifications: Written Confirmation

Raloxifene hydrochloride is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density. Raloxifene has been found to be effective in the treatment of gynecomastia (male breast development) in adolescents or osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.

Raloxifene was first introduced, for the prevention of postmenopausal osteoporosis, in 1997.It was subsequently approved for the treatment of postmenopausal osteoporosis in 1999 and to reduce the risk of breast cancer in certain women in 2007. It is available as a generic medication

Tolperisone Hydrochloride

CAS NO. 3644-61-9
Therapeutic Class: Antispastic agent (Muscle Relaxant)
Pharmacopoeia compliance: JP
Certifications: Written Confirmation

Tolperisone Hydrochloride, a piperidine derivative, is a centrally acting muscle relaxant. Tolperisone is indicated for use in the treatment of pathologically increased tone of the cross-striated muscle caused by neurological diseases (damage of the pyramidal tract, multiple sclerosis, myelopathy, encephalomyelitis) and of spastic paralysis and other encephalopathies manifested with muscular dystonia.

Zolpidem Tartrate

CAS NO. 99294-93-6
Therapeutic Class: Sedative (Treatment of trouble sleeping, treatment of insomnia)
Pharmacopoeia compliance: USP/Ph.Eur
Certifications:

Zolpidem is a non benzodiazepine of the imidazo pyridine class. It works by increasing GABA effects in the central nervous system by binding to GABA receptors at the same location as benzodiazepines. It generally has a half-life of two to three hours. This, however, is increased in those with liver problems.

Zolpidem was approved for medical use in the United States in 1992. It became available as a generic medication in 2007. In the United States it has a monthly cost of about US$8 for immediate release and US$66 for controlled release medication, as of 2017. In that country more than 10 million prescriptions are filled a year, making it one of the most commonly used treatments for sleeping problems.

Allopurinol

CAS NO. 315-30-0
Therapeutic Class: Antigout Preparations
Pharmacopoeia compliance: USP/Ph.Eur
Certifications:

Allopurinol is used to reduce urate formation, in conditions where urate deposition has already occurred or is predictable. The specific diseases and conditions where it is used include gouty arthritis, skin tophi, kidney stones, idiopathic gout, uric acid lithiasis, acute uric acid nephropathy, neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate.

Homotaurine

CAS NO. 3687-18-1
Therapeutic Class: Nutraceuticals
Pharmacopoeia compliance: USP/Ph.Eur
Certifications:

Homotaurine had been found to bind to soluble amyloid beta and inhibit the formation of neurotoxic aggregates It has also shown anticonvulsant activities, reduction in skeletal muscle tonus and hypothermic activity.

Homotaurine has been reported as a GABA antagonist, as well as a GABA agonist.

One study showed that Homotaurine suppressed ethanol-stimulated dopamine release, as well as ethanol intake and preference in rats in a way similar to the N-acetyl derivative of Homotaurine Acamprosate. Acamprosate was approved by the FDA in 2004 to treat alcohol dependence.

Bazedoxifene Acetate

CAS NO. 198481-33-3
Therapeutic Class: Anti- Alcoholism
Pharmacopoeia compliance: USP
Certifications:

Bazedoxifene or Bazedoxifene Acetate is a medication for bone problems and possibly (pending more study) for cancer. It is a third-generation selective estrogen receptor modulator (SERM). Since late 2013 it has had U.S. FDA approval for Bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausalosteoporosis. It is also being studied for possible treatment of breast cancer and pancreatic cancer.

Accamprostate Calcium

CAS NO. 77337-73-6
Therapeutic Class: Anti- Alcoholism
Pharmacopoeia compliance: USP
Certifications:

Acamprosate is useful when used along with counseling in the treatment of alcohol dependence. Over three to twelve months it increases the number of people who do not drink at all and the number of days without alcohol. It appears to work as well as naltrexone.

Acamprosate is also known by the brand name Campra is a drug used for treating alcohol dependence. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by blocking glutaminergic N-methyl-D-aspartate receptors, while gamma-aminobutyric acid type A receptors are activated. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol. Certain serious side effects include allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug.